210 related articles for article (PubMed ID: 31729968)
1. Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic.
Brown B; Weiss JL; Kolodny S; Meng X; Williams IM; Osborne JA
BMC Neurol; 2019 Nov; 19(1):287. PubMed ID: 31729968
[TBL] [Abstract][Full Text] [Related]
2. The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis.
Datt J; Baldock L; Pull E; Webber B
Mult Scler Relat Disord; 2016 Jan; 5():40-6. PubMed ID: 26856942
[TBL] [Abstract][Full Text] [Related]
3. Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study.
Limmroth V; Ziemssen T; Lang M; Richter S; Wagner B; Haas J; Schmidt S; Gerbershagen K; Lassek C; Klotz L; Hoffmann O; Albert C; Schuh K; Baier-Ebert M; Wendt G; Schieb H; Hoyer S; Dechend R; Haverkamp W
BMC Neurol; 2017 Jan; 17(1):11. PubMed ID: 28100182
[TBL] [Abstract][Full Text] [Related]
4. Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study.
Paolicelli D; Manni A; Direnzo V; D'Onghia M; Tortorella C; Zoccolella S; Trojano M
J Clin Pharmacol; 2015 Oct; 55(10):1131-6. PubMed ID: 25903516
[TBL] [Abstract][Full Text] [Related]
5. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.
Gold R; Comi G; Palace J; Siever A; Gottschalk R; Bijarnia M; von Rosenstiel P; Tomic D; Kappos L;
J Neurol; 2014 Feb; 261(2):267-76. PubMed ID: 24221641
[TBL] [Abstract][Full Text] [Related]
6. Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis.
Akbulak RÖ; Rosenkranz SC; Schaeffer BN; Pinnschmidt HO; Willems S; Heesen C; Hoffmann BA
Mult Scler Relat Disord; 2018 Jan; 19():44-49. PubMed ID: 29127856
[TBL] [Abstract][Full Text] [Related]
7. Mobitz type I and II atrioventricular blocks during fingolimod therapy.
Saccà F; Puorro G; Marsili A; Pane C; Russo CV; Lanzillo R; de Rosa A; Cittadini A; De Angelis G; Brescia Morra V
Neurol Sci; 2016 Sep; 37(9):1557-9. PubMed ID: 27225279
[TBL] [Abstract][Full Text] [Related]
8. First-dose effects of fingolimod: Pooled safety data from three phase 3 studies.
DiMarco JP; O'Connor P; Cohen JA; Reder AT; Zhang-Auberson L; Tang D; Collins W; Kappos L
Mult Scler Relat Disord; 2014 Sep; 3(5):629-38. PubMed ID: 26265275
[TBL] [Abstract][Full Text] [Related]
9. A Swiss real world best practice experience in three different clinical settings of the 6 hour fingolimod first dose observation procedure.
Ramseier SP; Roth S; Czaplinski A
BMC Pharmacol Toxicol; 2015 Apr; 16():7. PubMed ID: 25889400
[TBL] [Abstract][Full Text] [Related]
10. Fingolimod-related atrioventricular block in paediatric age group with multiple sclerosis: two case reports.
Kum YE; Pamukçu Ö; Canpolat M
Cardiol Young; 2023 Nov; 33(11):2384-2386. PubMed ID: 37170775
[TBL] [Abstract][Full Text] [Related]
11. Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors.
Bermel RA; Hashmonay R; Meng X; Randhawa S; von Rosenstiel P; Sfikas N; Kantor D
Mult Scler Relat Disord; 2015 May; 4(3):273-80. PubMed ID: 26008945
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
13. Vagomimetic effects of fingolimod: physiology and clinical implications.
Vanoli E; Pentimalli F; Botto G
CNS Neurosci Ther; 2014 Jun; 20(6):496-502. PubMed ID: 24836740
[TBL] [Abstract][Full Text] [Related]
14. Early safety and efficacy of fingolimod treatment in Denmark.
Voldsgaard A; Koch-Henriksen N; Magyari M; Sellebjerg F; Sørensen PS; Oturai AB
Acta Neurol Scand; 2017 Jan; 135(1):129-133. PubMed ID: 27910101
[TBL] [Abstract][Full Text] [Related]
15. Canadian Experience with Fingolimod: Adherence to Treatment and Monitoring.
Lapierre Y; O'Connor P; Devonshire V; Freedman MS; Kremenchutzky M; Yeung M; Schecter R
Can J Neurol Sci; 2016 Mar; 43(2):278-83. PubMed ID: 26890887
[TBL] [Abstract][Full Text] [Related]
16. Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study.
Ordoñez-Boschetti L; Rey R; Cruz A; Sinha A; Reynolds T; Frider N; Alvarenga R
Adv Ther; 2015 Jul; 32(7):626-35. PubMed ID: 26170105
[TBL] [Abstract][Full Text] [Related]
17. Delayed high-grade atrioventricular block requiring pacemaker implantation in a multiple sclerosis patient treated with fingolimod.
Feige J; Schernthaner C; Wipfler P; Sellner J
Mult Scler Relat Disord; 2020 Feb; 38():101515. PubMed ID: 31751857
[TBL] [Abstract][Full Text] [Related]
18. Delayed cardiac dysrhythmias after fingolimod administration.
Rosini JM; Rajasimhan S; Fellows SE; Nomura JT
Am J Emerg Med; 2015 Jul; 33(7):987.e1-3. PubMed ID: 25669873
[TBL] [Abstract][Full Text] [Related]
19. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
Meissner A; Limmroth V
Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
[TBL] [Abstract][Full Text] [Related]
20. Early tolerability and safety of fingolimod in clinical practice.
Ontaneda D; Hara-Cleaver C; Rudick RA; Cohen JA; Bermel RA
J Neurol Sci; 2012 Dec; 323(1-2):167-72. PubMed ID: 23040960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
